CVA in atrial fibrillation (primary prevention)
Last edited 06/2019 and last reviewed 05/2021
All patients with atrial fibrillation should be considered for anticoagulation. There is often a balance to be reached between the benefits of reducing the incidence of stroke and the possible complications of anticoagulation in old and infirm patients. Clearly the assessment of thromboembolic risk factors is important in making a sensible therapeutic decision.
An overview of five trials of warfarin in atrial fibrillation has shown that anticoagulation:
- reduced stroke by 68% compared to placebo
- reduced death by 33% compared to placebo
The target INR to maintain during anticoagulation should be between 2-3 (1).
Aspirin is a convenient drug for patients who cannot be anticoagulated. Aspirin is approximately half as effective as warfarin for the primary prevention of strokes. Aspirin is probably inadequate therapy for patients with the following risk factors:
- heart failure or left ventricular dysfunction
- uncontrolled hypertension
- females aged >75 years
The CHADS2 (2) scoring system and the CHA2DS2-VASc (3) score have subsequently been developed to identify patients with atrial fibrillation who require aspirin or oral anticoagulation therapy (see linked items).
- (1) NICE (2014). Atrial Fibrillation
- (2) Gage BF,Waterman AD, ShannonW, Boechler M, RichMW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285(22):2864-70.
- (3) European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010 Oct;31(19):2369-429.
atrial fibrillation (anticoagulation treatment related to risk of CVA)
stroke in atrial fibrillation (secondary prevention)
NICE guidance - dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (AF)
CHA2DS2-VASc score for stroke risk in atrial fibrillation (AF)